Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

The Alzheimer's disease neuroimaging initiative.

Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L.

Neuroimaging Clin N Am. 2005 Nov;15(4):869-77, xi-xii. Review.

2.

Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.

Caroli A, Prestia A, Wade S, Chen K, Ayutyanont N, Landau SM, Madison CM, Haense C, Herholz K, Reiman EM, Jagust WJ, Frisoni GB; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2015 Apr-Jun;29(2):101-9. doi: 10.1097/WAD.0000000000000071.

3.

Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play.

Jack CR Jr.

Radiology. 2012 May;263(2):344-61. doi: 10.1148/radiol.12110433. Review.

4.

A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative.

Braskie MN, Thompson PM.

Biol Psychiatry. 2014 Apr 1;75(7):527-33. doi: 10.1016/j.biopsych.2013.11.020. Epub 2013 Nov 28. Review.

5.

[Brain imaging of Alzheimer' disease: state of the art and perspectives for clinicians].

Trombella S, Assal F, Zekry D, Gold G, Giannakopoulos P, Garibotto V, Démonet JF, Frisoni GB.

Rev Med Suisse. 2016 Apr 20;12(515):795-8. Review. French.

PMID:
27276723
6.

Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.

Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, Doraiswamy PM; Alzheimer’s Disease Neuroimaging Initiative.

Radiology. 2013 Feb;266(2):583-91. doi: 10.1148/radiol.12120010. Epub 2012 Dec 11.

7.

Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative.

Weiner MW, Veitch DP.

Alzheimers Dement. 2015 Jul;11(7):730-3. doi: 10.1016/j.jalz.2015.05.007. Review.

PMID:
26194308
8.

Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.

Tosun D, Schuff N, Jagust W, Weiner MW; Alzheimer''s Disease Neuroimaging Initiative.

Neurodegener Dis. 2016;16(1-2):87-94. doi: 10.1159/000439257. Epub 2015 Nov 12.

PMID:
26560336
9.

Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L.

Alzheimers Dement. 2005 Jul;1(1):55-66.

10.

Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.

Ota K, Oishi N, Ito K, Fukuyama H; SEAD-J Study Group; Alzheimer's Disease Neuroimaging Initiative.

J Neurosci Methods. 2015 Dec 30;256:168-83. doi: 10.1016/j.jneumeth.2015.08.020. Epub 2015 Aug 28.

PMID:
26318777
11.

Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease.

Dukart J, Kherif F, Mueller K, Adaszewski S, Schroeter ML, Frackowiak RS, Draganski B; Alzheimer's Disease Neuroimaging Initiative.

PLoS Comput Biol. 2013 Apr;9(4):e1002987. doi: 10.1371/journal.pcbi.1002987. Epub 2013 Apr 4.

12.

Molecular imaging in genetics.

Leite J, Hespanhol R, Buchpiguel CA.

Neuroimaging Clin N Am. 2015 Feb;25(1):17-29. doi: 10.1016/j.nic.2014.09.005. Epub 2014 Oct 18. Review.

PMID:
25476510
13.

Alzheimer's disease.

Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM.

Lancet. 2016 Jul 30;388(10043):505-17. doi: 10.1016/S0140-6736(15)01124-1. Epub 2016 Feb 24. Review.

PMID:
26921134
14.

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008. Review.

15.

Integrating ADNI results into Alzheimer's disease drug development programs.

Cummings JL.

Neurobiol Aging. 2010 Aug;31(8):1481-92. doi: 10.1016/j.neurobiolaging.2010.03.016. Epub 2010 May 5. Review.

16.

Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease.

Small GW.

J Geriatr Psychiatry Neurol. 2006 Sep;19(3):180-5. Review.

PMID:
16880360
17.

Early detection of Alzheimer's disease using neuroimaging.

Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ.

Exp Gerontol. 2007 Jan-Feb;42(1-2):129-38. Epub 2006 Jul 12. Review.

PMID:
16839732
18.

Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.

Jack CR Jr, Barnes J, Bernstein MA, Borowski BJ, Brewer J, Clegg S, Dale AM, Carmichael O, Ching C, DeCarli C, Desikan RS, Fennema-Notestine C, Fjell AM, Fletcher E, Fox NC, Gunter J, Gutman BA, Holland D, Hua X, Insel P, Kantarci K, Killiany RJ, Krueger G, Leung KK, Mackin S, Maillard P, Malone IB, Mattsson N, McEvoy L, Modat M, Mueller S, Nosheny R, Ourselin S, Schuff N, Senjem ML, Simonson A, Thompson PM, Rettmann D, Vemuri P, Walhovd K, Zhao Y, Zuk S, Weiner M.

Alzheimers Dement. 2015 Jul;11(7):740-56. doi: 10.1016/j.jalz.2015.05.002.

19.

Prevalence and prognosis of prodromal Alzheimer's disease as assessed by magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography in a community: reanalysis from the Osaki-Tajiri Project.

Meguro K, Akanuma K, Meguro M, Yamaguchi S, Ishii H, Tashiro M.

Psychogeriatrics. 2016 Mar;16(2):116-20. doi: 10.1111/psyg.12131. Epub 2015 Jun 26.

PMID:
26114837
20.

Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans.

Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, Risacher SL, Nho K, Huentelman MJ, Craig DW, Thompson PM, Stein JL, Moore JH, Farrer LA, Green RC, Bertram L, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):265-73. doi: 10.1016/j.jalz.2010.03.013.

Supplemental Content

Support Center